Publication Name	World Journal of Gastroenterology
Manuscript ID	92474
Country	Italy

Received	2024-01-26 20:53
Peer-Review Started	2024-01-26 20:53
To Make the First Decision
Return for Revision	2024-06-18 05:30
Revised	2024-06-26 13:33
Second Decision	2024-07-18 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-07-18 07:09
Articles in Press	2024-07-18 07:09
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-07-22 09:38
Typeset the Manuscript	2024-07-31 01:47
Publish the Manuscript Online	2024-08-09 12:51

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction–associated steatotic liver disease
Manuscript Source	Invited Manuscript
All Author List	Maurizio Soresi and Lydia Giannitrapani
Funding Agency and Grant Number
Corresponding Author	Maurizio Soresi, MD, Associate Professor, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Via del Vespro 141, Palermo 90127, Italy. maurizio.soresi@unipa.it
Key Words	Non-alcoholic fatty liver disease; Glucagon-like peptide 1; Semaglutide; Liver fibrosis; Therapy
Core Tip	In this editorial, we comment on Yin et al’s recently published Letter to the editor. Despite the widespread diffusion, up to now there have been no drugs capable of reliably blocking the evolution of non-alcoholic steato-hepatitis towards advanced stages of fibrosis. We agree with Yin et al that glucagon-like peptide receptor agonists monotherapy does not perform well as an antifibrotic therapy. The use of combination therapy according to disease stage and co-morbidities, will be also the challenge for the near future.
Publish Date	2024-08-09 12:51
Citation	<p>Soresi M, Giannitrapani L. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction–associated steatotic liver disease. <i>World J Gastroenterol</i> 2024; 30(30): 3541-3547</p>
URL	https://www.wjgnet.com/1007-9327/full/v30/i30/3541.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i30.3541

Full Article (PDF)	WJG-30-3541-with-cover.pdf
Manuscript File	92474_Auto_Edited_012645.docx
Answering Reviewers	92474-answering-reviewers.pdf
Audio Core Tip	92474-audio.m4a
Conflict-of-Interest Disclosure Form	92474-conflict-of-interest-statement.pdf
Copyright License Agreement	92474-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	92474-non-native-speakers.pdf
Peer-review Report	92474-peer-reviews.pdf
Scientific Misconduct Check	92474-scientific-misconduct-check.png
Scientific Editor Work List	92474-scientific-editor-work-list.pdf
CrossCheck Report	92474-crosscheck-report.pdf